本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Enlivex Therapeutics Ltd.

1.18
+0.05004.42%
盘后1.180.00000.00%16:34 EDT
成交量:14.11万
成交额:16.86万
市值:2,794.86万
市盈率:-1.78
高:1.21
开:1.16
低:1.15
收:1.13
数据加载中...
2025/05/09

SEC问询函

Form CORRESP - Correspondence
2025/05/01

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/14

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/04/30

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/10

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/05/03

SEC问询函

CORRESP [Cover] - Correspondence
2022/04/29

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/06/04

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/04/30

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/10

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/02/09

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2020/08/14

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/05/18

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/30

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/13

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/18

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/05

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/26

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/24

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/14

超过5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals